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Modification of established rejection of 
canine kidney and liver 
homografts with 
antilymphocyte 
gamma-G globulin 
T ability of h,',rologo"" antilympho-
cyte serum (ALS) or its globulin derivative 
(ALG) to mitigate or even prevent homo-
graft rejection is well known. In early investi-
gations with skin homotransplantation in 
inbred rodents, it was shown that ALS given 
even several days after arrival of the homo-
graft resulted in definite prolongation of 
transplant survival,4,7 This communication 
concerns an extension of this kind of study 
in mongrel dogs that were subjected to 
renal or liver transplantation and were not 
treated until the onset of rejection. 
METHODS 
Renal homotransplantation and simulta-
neous bilateral nephrectomy were performed 
in 10 test and 10 control mongrel dogs which 
weighed 10 to 20 kilograms. Postoperatively, 
blood urea nitrogens (BUN's) were per-
formed daily. In addition, one animal with 
orthotopic liver transplantation was included 
and followed with standard liver function 
tests. Autopsy was carried out in all but two 
dogs which are still alive after 45 and 100 
days. 
The sole antirejection therapy in the 
treated group was with horse antidog-
lymphocyte globulin (ALG). The ALG con-
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sisted of a nearly pure gamma-G globulin 
that had been removed from the horse serum 
with a diethylaminoethyl cellulose batch tech-
nique.5 The material had a protein content 
of 2.8 Gm. percent and leukoagglutinin, 
hemagglutin, hemolysin, and thromboagglu-
tinin titers of 1 :4,000, 1: 1,000, 1 :4, and 
1: 12, respectively. The individual intramus-
cular doses were based on the leukoagglutinin 
titers and were calculated to provide 1,000 
units per kilogramll or about 0.7 mg. per 
kilogram per day. The same ALG when 
administered daily from the time of opera-
tion had previously been shown by Kashiwagi 
and co-workers5 to permit a mean post-
operative survival after renal homotransplan-
tation of 23 days. 
In the experiments with kidney transplan-
tation, ALG therapy was not started until 
the BUN had begun to rise secondarily after 
several days of initial normal renal function. 
It was then given daily until death or for 
at least 2 months from the time the BUN 
reached or exceeded 40 mg. percent. One 
week after transplantation the recipient of 
the liver homograft developed rejection and 
was given injections of ALG for 3 consecu-
tive days but not thereafter. 
RESULTS 
Control animals. For unexplained reasons, 
survival was unusually prolonged in the un-
treated recipients of renal homografts (Table 
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Table I. Data on untreated control dogs subjected to renal homotransplantation 
and test animals in which ALG was started after the onset of uremia 
Survival with BUN> 40 mg. 
Experi- Total survival % 
ment Day BUN> 40 mg. % I (Days) (Days) 
No. Control I Treated I Control I Treated Control I Treated 
1 11 13 30 25 19 12 
2 30 5 33 13 3 8 
3 9 14 13 17 4 3 
4 4 7 10 13 6 6 
5 14 6 20 9 6 3 
6 4 8 9 32 5 24 
7 6 10 7 20 1 10 
8 10 11 16 29 6 18 
9 6 9 11 50* 5 41* 
10 8 7 12 13 4 6 
-- --
Mean 10.2 9.0 16.1 22.1 5.9 13.1 
* Although survival credit was limited to 50 days, this animal is still alive with normal renal function after 100 days. 
I), averaging 16.1 (range 7 to 33) days. 
Three of the animals lived for 20, 30, and 
33 days. 
BUN elevations to more than 40 mg. per-
cent occurred between the fourth and thir-
tieth days (10.2 days average). Thereafter, 
the average survival was 5.9 days. The long-
est survival after this level of uremia became 
established was 19 days. The rise in BUN 
in the longest-surviving dog was at 30 days 
with death following 3 days later. There 
were no examples of spontaneous reversal 
of the azotemia. The histologic features of 
all the homografts were those of typical 
rejection. 
Treated animals. One of the recipients of 
a renal homograft is still alive with a normal 
BUN after 100 days. Limiting credit for this 
animal to 50 days, the mean survival for 
the entire series was 22.1 days (Table I). 
Lymphopenia was commonly but not in-
variably observed after starting ALG treat-
ment, but its presence or absence was not 
well correlated with subsequent survival. 
The elevations in BUN to more than 40 
mg. percent were observed 5 to 14 days after 
operation. Subsequent survival, with the 
ceiling of 50 days for the longest-living dog, 
was 13.1 days. Four of the animals had 
some definite evidence of reversal of the 
azotemia although in only two did the BUN 
revert to normal (Fig. 1); in the two latter 
experiments, the peak BUN was recorded 
at 141 and 53 mg. percent, respectively. Ul-
timately, all the animals but the one still 
alive developed fatal uremia. All of the nine 
kidneys examined after death had histologic 
evidence of rejection although his was less 
marked than in the control experiments. 
The recipient of the liver homograft 
developed rejection 7 days after transplanta-
tion, was given three injections of ALG, and 
is still alive 45 days postoperatively despite 
slowly progressive deterioration of hepatic 
function. 
DISCUSSION 
In these experiments, there was evidence 
that ALG therapy slowed the tempo and 
vigor of rejection even when treatment was 
started after this process was well advanced. 
The crude survival was increased by about 
a week. Of even greater significance was the 
fact that death after the onset of uremia 
was delayed from 5.9 days in the control 
animals to 13.1 days in the test series. Finally, 
there was apparent reversal of rejection, at 
least for brief periods, in four of the ten 
kidney recipients and in the liver recipient. 
These findings were not surprising in 
view of the previous reports that ALS or 
ALG can prevent or blunt the expression of 
pre-existing immunization statesl - 3 , 8, 12-14 in-
cluding that of a second-set reaction.G, 7, 9, 10 
548 Smith et al. 
... 
.. 
co. 
250 
200 
... 150 
.§ 
- TREATED DOG 6 
- - - TREATED DOG 9 
Surgery 
September 1969 
EXPIRED 
32 DAYS 
o~----~------~----~------~------~----~----~ o 5 10 15 20 25 30 35 ob~i TIME I N DAYS 
TRANSPLANTATION 
Fig. 1. Blood urea nitrogen levels in two dogs which received delayed treatment with anti-
lymphocyte gamma-G globulin (ALG). Therapy was initiated (arrows) when the BUN second-
arily rose above 40 mg. percent, 8 and 9 days, respectively, after renal transplantation, and 
continued thereafter in doses of 1,000 units per kilogram per day. Dog 6 died of uremia 32 
days postoperatively, 24 days after the onset of rejection. Dog 9 is alive with normal renal 
function more than 100 days after transplantation. 
However, the magnitude of the effect was 
limited and resulted in only one long-term 
survivor in the kidney series. Presumably, a 
greater therapeutic benefit might have been 
obtained if the doses had been larger or if 
treatment had been started at an earlier 
time. 
SUMMARY 
Heterologous ALG was administered to 
ten canine recipients of renal homografts 
and one recipient of an orthotopic liver. 
Treatment was started after rejection was 
well established. Death from homograft fail-
ure was thereby significantly delayed and in 
several experiments the rejection was at 
least partially reversed. 
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